Grab Holdings Ltd. vs Revvity Inc — how do they compare? Grab Holdings Ltd. trades at $3.21 (market cap $12.72B), while Revvity Inc trades at $154.49 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Revvity Inc for 12 Days on average.
| GRAB | RVTY | |
|---|---|---|
Market Cap | $12.72B | $16.98B |
Volume | 65,352,859 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $6.17 | $157.36 |
52-Week Low | $2.80 | $82.26 |
Typical Hold Time | 94 Days | 12 Days |
Enterprise Value | $8.46B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Grab Holdings (GRAB) trades at $3.195, up 3.73% today, showing strong momentum after recent volatility. The stock demonstrates improving fundamentals with revenue growing from $2.8B in 2024 to $3.37B in 2025 and achieving profitability with $268M net income. Recent Q2 2026 earnings beat expectations with $0.06 EPS versus $0.05 expected, while technical indicators show bearish signals despite neutral oscillators. The company's $1.49B acquisition of Atome Financial positions it for financial services expansion.
Grab presents a compelling turnaround story with accelerating revenue growth and recent profitability. The strong analyst consensus (91.67% buy ratings) and $30M CEO share purchase signal confidence, though technical weakness and competitive pressures in Southeast Asia's ride-hailing market warrant caution. Key catalysts include continued execution on profitability targets and successful integration of Atome acquisition.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →